Clinical Trials Browser

Recruiting × OTHER × onvansertib × Clear all

Pancreatic Neoplasms

NCT05549661 2026-02-23

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT05450965 2025-12-17

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Phase 2 Recruiting

37 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06736717 2025-02-06

PANCONVA

Phase 1/2 Recruiting

21 enrolled

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

PANCONVA